{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:59:59Z","timestamp":1773885599980,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102778","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:26:16Z","timestamp":1763637976000},"page":"102778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential"],"prefix":"10.1016","volume":"36","author":[{"given":"Tanya","family":"Hundal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqing","family":"Qie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha E.","family":"Gadd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Brim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isas","family":"Vazquez-Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-929X","authenticated-orcid":false,"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102778_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fimmu.2016.00648","article-title":"T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients","volume":"7","author":"Klaver","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102778_bib2","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2019-131839","article-title":"Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable","volume":"134","author":"Cranert","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102778_bib3","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102778_bib4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102778_bib5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0092-8674(02)01194-7","article-title":"The organizing principle in the formation of the T cell receptor-CD3 complex","volume":"111","author":"Call","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102778_bib6","doi-asserted-by":"crossref","first-page":"E6649","DOI":"10.1073\/pnas.1611445113","article-title":"A conserved alphabeta transmembrane interface forms the core of a compact T-cell receptor-CD3 structure within the membrane","volume":"113","author":"Krshnan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102778_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102778_bib8","article-title":"47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"16","author":"Kocoglu","year":"2022","journal-title":"Immun. Oncol. Technol."},{"key":"10.1016\/j.omtn.2025.102778_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2025.102778_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102778_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007652","article-title":"Robust activation of microhomology-mediated end joining for precision gene editing applications","volume":"14","author":"Ata","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2025.102778_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/nar\/gkaa1156","article-title":"Deploying MMEJ using MENdel in precision gene editing applications for gene therapy and functional genomics","volume":"49","author":"Martinez-Galvez","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102778_bib13","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered Universal CD19\/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102778_bib14","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2024-CT002","article-title":"Abstract CT002: CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","volume":"84","author":"Pal","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102778_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102778_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102778_bib17","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102778_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13059-021-02462-4","article-title":"Effective control of large deletions after double-strand breaks by homology-directed repair and dsODN insertion","volume":"22","author":"Wen","year":"2021","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2025.102778_bib19","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/s41467-021-24017-8","article-title":"AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102778_bib20","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1038\/s41467-022-33346-1","article-title":"Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption","volume":"13","author":"Xin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102778_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s40880-015-0052-4","article-title":"Wnt3a: functions and implications in cancer","volume":"34","author":"He","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102778_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cell.2015.11.052","article-title":"Regulation of T Cell Receptor Signaling by DENND1B in TH2 Cells and Allergic Disease","volume":"164","author":"Yang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102778_bib23","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2025.102778_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102778_bib25","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1007\/s00262-023-03537-w","article-title":"Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies","volume":"72","author":"Luo","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2025.102778_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.716","article-title":"Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells","volume":"5","author":"Qie","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.omtn.2025.102778_bib27","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","article-title":"Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions","volume":"69","author":"Dong","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2025.102778_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2024.02.008","article-title":"CAR T-cell therapy-paving the way for sensitized kidney transplant patients","volume":"105","author":"Jarmi","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2025.102778_bib29","article-title":"Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1","volume":"32","author":"Luo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omtn.2025.102778_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.immuni.2018.09.007","article-title":"The T Cell Antigen Receptor alpha Transmembrane Domain Coordinates Triggering through Regulation of Bilayer Immersion and CD3 Subunit Associations","volume":"49","author":"Brazin","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2025.102778_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41586-019-1537-0","article-title":"Structural basis of assembly of the human T cell receptor-CD3 complex","volume":"573","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102778_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102778_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215736","article-title":"Gene knockout in cellular immunotherapy: Application and limitations","volume":"540","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2025.102778_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102778_bib35","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2023.02.011","article-title":"Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34(+) hematopoietic stem and progenitor cells","volume":"31","author":"Cromer","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102778_bib36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102778_bib37","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102778_bib38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102778_bib39","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102778_bib40","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jcyt.2025.04.068","article-title":"A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14(-)CD127(+) T cells for chimeric antigen receptor T-cell manufacture","volume":"27","author":"Luo","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtn.2025.102778_bib41","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omtn.2025.102778_bib42","article-title":"BAFF - R BISPECIFIC T - CELL ENGAGER ANTIBODY","volume":"vol. US20200199232A1","author":"Qin","year":"2020"},{"key":"10.1016\/j.omtn.2025.102778_bib43","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41551-024-01255-x","article-title":"Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies","volume":"8","author":"Kapetanovic","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2025.102778_bib44","article-title":"Bispecific antibodies in indolent B-cell lymphomas","volume":"14","author":"Radhakrishnan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102778_bib45","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","article-title":"A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers","volume":"46","author":"Dietz","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.omtn.2025.102778_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/cpim.97","article-title":"T Cell Receptor Engineered Lymphocytes for Cancer Therapy","volume":"129","author":"Rollins","year":"2020","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.omtn.2025.102778_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-1759(03)00002-4","article-title":"Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells","volume":"275","author":"Nguyen","year":"2003","journal-title":"J. Immunol. Methods"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:39:33Z","timestamp":1773866373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003324"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102778","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102778"}}